Fortune MNC 500 India 2026 edition
Rank#304- Total income
- ₹1,677 Cr
- Profit
- ₹194 Cr
Last year #293
Fresenius Kabi
Founded: 1999 • Age: 27 yrs Fortune MNC 500 · #304
Healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals.
About Fresenius Kabi
Fresenius Kabi is a Healthcare company founded in 1999. It operates as a healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals. Fresenius Kabi has completed 4 acquisitions, including Akorn, Fenwalinc and Ivenix. Fresenius Kabi offers products and services including IV Drugs and Infusion Therapy and Medical Nutrition. Its focus areas include Pharmaceuticals, IV Drugs and Infusion Therapy, Anesthetics and Oncology and Medical Technology. Its legal entity is Fresenius Kabi AG.
Company details
Fresenius Kabi is recognized as a global provider of healthcare products and services, with a focus on lifesaving medicines and technologies for critically ill patients. Its portfolio includes IV drugs, medical nutrition, and biopharmaceuticals that are utilized to support patient care worldwide. Sustainability efforts are emphasized, including reductions in emissions and community support, while maintaining high-quality standards. The companys global presence and commitment to ethical practices are noted in its operations from Bad Homburg, Germany, touching the lives of millions annually through innovative healthcare solutions.
Fresenius Kabi is ranked #304 on the Fortune MNC 500 India (2026).
Recognitions & Rankings of Fresenius Kabi
Operational Areas
Key Metrics
- Investments & AcquisitionsAkorn
& 3 more
Products & Services of Fresenius Kabi
Fresenius Kabi offers a comprehensive portfolio of products and services, including IV Drugs and Infusion Therapy and Medical Nutrition.
IV Drugs and Infusion Therapy
Pharmaceuticals
IV therapy products are supplied by Fresenius Kabi for anesthetics, oncology, anti-infectives, and critical care to enhance patient outcomes.
Medical Nutrition
Nutrition
Specialized nutrition solutions are offered by Fresenius Kabi, including parenteral and enteral nutrition for various patient needs.
People of Fresenius Kabi
367 people are tracked at Fresenius Kabi (162 in leadership, 205 in team).
| Name | Role | Group |
|---|---|---|
Steve Phillips | Senior Director, Immunology Biosimilar Sales | Leadership |
Thorben Adami | Director Strategic Data Analytics | Corporate Development | Leadership |
Svenja Reith | Senior Director Human Resources / Head Of Human Resources Department | Leadership |
Pierluigi Antonelli | President & Chief Executive Officer | Leadership |
Andreas Duenkel | CFO & Chief Compliance Officer | Leadership |
Marc Crouton | President, Region Europe | Leadership |
Marc-Alexander Mahl | President, Pharma & Nutrition | Leadership |
Christian Hauer | President, MedTech | Leadership |
Matthias Tyssen | Head of Corporate Development & EVP | Leadership |
Chris Mellard | Vice President Qa, Special Projects | Leadership |
Niklas Sand | HR Business Partner | Leadership |
Antonio Ricci | VP I&d API | Leadership |
Anna Violant Gómez | Head Of Human Resources Region International | Leadership |
Heinrich Martens | Vice President Regulatory Affairs / Medical Devices | Leadership |
Wolfgang Gleichweit | Vice President Quality Assurance Business Unit Nutrition | Leadership |
Sang-Jin Pak | President, Biopharma | Leadership |
Fabrizio Dolfi | VP Head Of Medical Affairs | Leadership |
Franz Kainz | Senior Vice President, B2b Operations | Leadership |
Niamh Furey | Vice President Commercial Operations Biopharmaceuticals EU & Row Fresenius Kabi | Leadership |
Helmut Kogler | Vice President - Head Of Commercial Biosimilars Germany | Leadership |
347 more people are available in the full profile.
Premium access
Complete people profiles for Fresenius Kabi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fresenius Kabi
Fresenius Kabi has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Akorn, Fenwalinc and Ivenix.
Acquisitions
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibodies, cytokines, and hormones are developed, manufactured, and commercialized. | mabxience.com | Lugano, Switzerland | 2009 | Mar 2022 | $551.22M | |
Infusion management systems are developed with wireless web-based architecture. | ivenix.com | Amesbury, United States | 2001 | Mar 2022 | $240M | |
Injectable and ophthalmic pharmaceutical products were manufactured across therapeutic areas. | akorn.com | Lake, United States | 1948 | Apr 2017 | •••• | |
Portfolio of products for transfusion medicine and cell therapy. | fenwalinc.com | Lake Zurich, United States | 1949 | Jul 2012 | •••• |
Premium access
Complete acquisition details for Fresenius Kabi
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Fresenius Kabi
Websites that share an audience with Fresenius Kabi (fresenius-kabi.com).
Similar websites
Websites whose visitors overlap most with Fresenius Kabi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| huons.com | 92% | 54.2K | #591,111 | View details | |
| fresenius.com | 86% | 59.2K | #581,297 | View details | |
| fresenius-kabi-oncology.com | 83% | 1.7K | #9,088,911 | View details | |
| eisai.com | 77% | 74.5K | #534,857 | View details | |
| sandoz.com | 77% | 195.3K | #232,061 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
Premium access
All 13 similar websites and full traffic analytics for Fresenius Kabi
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Fresenius Kabi (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Upgrade to premium
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fresenius Kabi
Premium access
Complete news archive for Fresenius Kabi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fresenius Kabi
Fresenius Kabi was founded in 1999.
Fresenius Kabi is recognized as a global provider of healthcare products and services, with a focus on lifesaving medicines and technologies for critically ill patients. Its portfolio includes IV drugs, medical nutrition, and biopharmaceuticals that are utilized to support patient care worldwide. Sustainability efforts are emphasized, including reductions in emissions and community support, while maintaining high-quality standards. The companys global presence and commitment to ethical practices are noted in its operations from Bad Homburg, Germany, touching the lives of millions annually through innovative healthcare solutions.
Fresenius Kabi offers IV Drugs and Infusion Therapy and Medical Nutrition.
Fresenius Kabi operates through Fresenius Kabi Ag.